Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the united states, 2009-2012

Clinical Infectious Diseases

Volumn 58, Issue 3, 2014, Pages 423-431

  Hurt, Christopher B ^a,d   Sebastian, Joseph ^b   Hicks, Charles B ^c   Eron, Joseph J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LABORATORY CORPORATION OF AMERICA   (United States)

^c DUKE UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

antiretroviral resistance; dolutegravir; elvitegravir; human immunodeficiency virus; raltegravir

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL DECISION MAKING; DEMOGRAPHY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; UNITED STATES; WILD TYPE;

ANTIRETROVIRAL RESISTANCE; DOLUTEGRAVIR; ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS; RALTEGRAVIR;

ADULT; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PREVALENCE; UNITED STATES;

EID: 84892766007     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit697     Document Type: Article

References (36)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Washington, DC: US Department of Health and Human Services, 2009.
2. United States Food and Drug Administration. Drug approval package: Isentress (raltegravir) NDA #022145. Available at: http://www.accessdata. fda.gov/drugsatfda-docs/nda/2007/022145-Isentress.cfm. Accessed 24 June 2013.
3. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin Infect Dis 2010; 50:605-12.
4. Rockstroh JK, Lennox JL, Dejesus E, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53:807-16.
5. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, co-bicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritona-vir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 2012; 379:2429-38.
6. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-48.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Washington, DC: US Department of Health and Human Services, 2013.
8. United States Food and Drug Administration. Drug approval package: Stribild (cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fu-marate) NDA #203100. Available at: http://www.accessdata.fda.gov/drugsatfda- docs/nda/2012/203100Orig1s000TOC.cfm. Accessed 24 June 2013.
9. United States Food and Drug Administration. Drug approval package: Tivicay (dolutegravir) NDA #204790. Available at: http://www.accessdata. fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview& DrugName=TIVICAY. Accessed 20 August 2013.
10. Eron JJ, Cooper DA, Steigbigel RT, et al. Efficacy and safety of raltegra-vir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis 2013; 13:587-96.
11. Rockstroh JK, Dejesus E, Lennox JL, et al. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricita-bine in treatment-naive HIV-1 infected patients: final five-year results from STARTMRK. J Acquir Immune Defic Syndr 2013; 63:77-85.
12. Hu Z, Kuritzkes DR. Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitness. J Acquir Immune Defic Syndr 2010; 55:148-55.
13. Geretti AM, Armenia D, Ceccherini-Silberstein F. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 2012; 25:677-86.
14. Malet I, Delelis O, Soulie C, et al. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother 2009; 63:795-804.
15. White K, Abram M, Kulkarni R, Rhee M, Szwarcberg J, Miller MD. Emergent drug resistance from the HIV-1 phase 3 elvitegravir/cobici-stat/emtricitabine/ tenofovir disoproxil fumarate studies through week 96. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013. Abstract 596.
16. Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Anti-microb Agents Chemother 2011; 55:813-21.
17. Huang W, Frantzell A, Fransen S, Petropoulos CJ. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvite-gravir. Antimicrob Agents Chemother 2013; 57:4105-13.
18. Métifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011; 25:1175-8.
19. Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013; 207:740-8.
20. Nichols G, Mills A, Grossberg R, et al. Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3. In: 11th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, 2012.
21. Hatano H, Lampiris H, Fransen S, et al. Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr 2010; 54:389-93.
22. Quashie PK, Mesplede T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86:2696-705.
23. Mesplède T, Quashie PK, Osman N, et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013; 10:22.
24. Pozniak A, Mingrone H, Shuldyakov A, et al. Dolutegravir vs raltegravir in ART-experienced, integrase-naive subjects: 24-week interim results from SAILING (ING111762). In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013. Abstract 179LB.
25. Malet I, Fourati S, Charpentier C, et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02-AG HIV-1 subtype. J Antimicrob Chemother 2011; 66:2827-30.
26. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204-14.
27. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83:11440-6.
28. Johnson VA, Calvez V, Gunthard HF, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013; 21:6-14.
29. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-18.
30. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009; 4:e4724.
31. Underwood MR, Johns BA, Sato A, Martin JN, Deeks SG, Fujiwara T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012; 61:297-301.
32. Dolling D, Nelson M, Schwenk A, et al. Rapid increase in the frequency of wild-type HIV-1 drug resistance reports among ART-experienced patients: UK. In: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013. Abstract 594.
33. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. Lancet Infect Dis 2011; 11:907-15.
34. Boyd S, Maldarelli F, Sereti I, et al. Transmitted raltegravir resistance in an HIV-1 CRF-AG-infected patient. Antivir Ther 2011; 16:257-61.
35. Young B, Fransen S, Greenberg K, et al. Transmission of integrase strand-transfer inhibitor, multidrug resistant HIV-1: case report and natural history of response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011; 16:253-6.
36. Hurt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther 2011; 16:137-40.